OSU-6162 is under clinical development by Saniona and currently in Phase II for Bipolar I Disorder. According to GlobalData, Phase II drugs for Bipolar I Disorder does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OSU-6162 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OSU-6162 (PNU-96391) is under development for the treatment of bipolar I, bipolar II disorder and SSRI/SNRI-resistant depression. The drug candidate is administered orally in the form of coated tablet. It has two enantiomers. Both enantiomers of OSU6162 has medium intrinsic activity and act as partial agonists at 5-HT2A receptors and low intrinsic activity partial agonists at D2 receptors. It was also under development for the treatment of Parkinson's disease, Huntington's disease, narcolepsy, multiple sclerosis, myalgic encephalomyelitis, chronic fatigue, alcohol dependence, dyskinesia in Parkinson's disease schizophrenia, residual symptoms after stroke.
Saniona is a biopharmaceutical company that discovers, develops, and delivers treatments for rare diseases. It is investigating Tesomet, a combination of tesofensine and metoprolol against hypothalamic obesity and Prader-Willi syndrome. The company is also evaluating SAN711, a positive allosteric modulator of GABAA a3 receptors to treat rare neuropathic disorders; and SAN903, an inhibitor of calcium-activated potassium ion channel (KCa3.1) targeting rare inflammatory and fibrotic disorders. Saniona utilizes its proprietary ion channel drug discovery engine anchored by IONBASE to discover its products. It works in partnership with Productos Medix SA de CV, Novartis AG, Boehringer Ingelheim International GmbH, and other pharmaceutical companies. It has operational presence in Denmark and the US. Saniona is headquartered in Ballerup, Denmark.
For a complete picture of OSU-6162’s drug-specific PTSR and LoA scores, buy the report here.